NovaBridge Executive Chairman Fu Wei to Buy Up to $5M in Open Market Transactions

martes, 20 de enero de 2026, 7:02 am ET1 min de lectura
NBP--

Fu Wei, Executive Chairman of NovaBridge Biosciences, plans to purchase up to $5 million of the company's ADSs in open market transactions. This follows a positive Phase 1b dose expansion data announcement for givastomig in first-line metastatic gastric cancer. NovaBridge is a biotechnology platform company with a differentiated pipeline, including givastomig, VIS-101, and uliledlimab.

NovaBridge Executive Chairman Fu Wei to Buy Up to $5M in Open Market Transactions

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios